Close

NanoViricides files FluCide pre-IND to FDA

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Insulated Pallet Protection in Temperature-Sensitive Pharmaceutical Shipping

In the pharmaceutical industry, products frequently require very specific...

Litmys and PharmaACE Establish Strategic Partnership for Market Projections

Life sciences consulting firms Litmys and PharmaACE have officially...

Blackstone Provides Up to $1.5 Billion for Pfizer’s Obesity Drug Candidate

Private equity firm Blackstone Life Sciences has agreed to...
- Advertisement -

NanoViricides has submitted a pre- Investigational New Drug (IND) briefing document of its anti-influenza drug candidate, FluCide to the US Food and Drug Administration (FDA).

In a lethal influenza infection mouse model, FluCide has shown to be highly effective in controlling viral influenza compared with TamiFlu, the current treatment standard. The company intends to use the pre-IND application to obtain concurrence from the FDA on its planned toxicological studies, as well as the general plan for the early human clinical trials.

The pre-IND Meeting is expected to take place in March-April 2012. Additionally, the company plans to discuss its Chemical Manufacturing and Controls (CMC) program for the cGMP manufacture of FluCide in the meeting. NV-INF-1, the selected candidate drug substance of the FluCide program, has shown viral load reduction of 1.3 logs to 3 logs in various studies.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

Insulated Pallet Protection in Temperature-Sensitive Pharmaceutical Shipping

In the pharmaceutical industry, products frequently require very specific...

Litmys and PharmaACE Establish Strategic Partnership for Market Projections

Life sciences consulting firms Litmys and PharmaACE have officially...

Blackstone Provides Up to $1.5 Billion for Pfizer’s Obesity Drug Candidate

Private equity firm Blackstone Life Sciences has agreed to...

How Biopharmaceutical Research Is Shaping the Future of Cancer Treatment

Cancer is no longer viewed solely as a clinical...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »